Neumora Therapeutics, Inc. $NMRA Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 392.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 534,044 shares of the company’s stock after acquiring an additional 425,633 shares during the quarter. GSA Capital Partners LLP owned 0.32% of Neumora Therapeutics worth $956,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Legacy Private Trust Co. boosted its holdings in Neumora Therapeutics by 35.7% in the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Neumora Therapeutics by 10.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after purchasing an additional 6,233 shares during the last quarter. Invesco Ltd. raised its stake in shares of Neumora Therapeutics by 6.8% in the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after purchasing an additional 8,383 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics in the third quarter worth about $31,000. Finally, Cerity Partners LLC raised its stake in shares of Neumora Therapeutics by 7.2% in the second quarter. Cerity Partners LLC now owns 324,219 shares of the company’s stock worth $238,000 after purchasing an additional 21,714 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $1.85 on Friday. Neumora Therapeutics, Inc. has a 1-year low of $0.66 and a 1-year high of $3.65. The company has a market cap of $342.77 million, a price-to-earnings ratio of -1.39 and a beta of 3.02. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. The stock’s 50-day moving average is $2.20 and its two-hundred day moving average is $2.35.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Analysts forecast that Neumora Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on NMRA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Guggenheim reiterated a “buy” rating and set a $14.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.